Clinical Trial Update: Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on allogeneic CD19 CAR-T cells for relapsed/refractory B-cell acute lymphoblastic leukemia (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Leukemia

Drugs mentioned

• Allogeneic CD19 CAR-T cells

Snippet

Sponsor: Shenzhen University General Hospital | Conditions: Relapse Leukemia, Refractory Leukemia | Phase 1, Phase 2 | Status: UNKNOWN